Clinical Trial Update: IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating intensity-modulated radiotherapy (IMRT) combined with toripalimab in unresectable locally recurrent nasopharyngeal carcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms | Phase 2 | Status: UNKNOWN